Calendar
Top-down
A look at earnings from the view of macro-economists and market technicians
Market Overview
Heat Map
Sentiment
Technicals
Retail Sales
Pricing
Manu-facturing
Economic Cycle
Bottom-up
A bottom-up view of earnings from professional equity analysts
Earnings Highlights
Date Trades
Earnings News
Pivots
Earnings Cycle
Sector Analysis
Investor
Trader
Support
Documentation, research, and support for the information provided
Indicators
Results
About Us
Library
Contact Us
Plays
Score
Grade
Sign In
Sign In
or
Register
Forgot Password?
OR
Sign in using:
Don't have an account?
Register
RARE
$21.25
Ultragenyx Pharmaceu
($.21)
(.98%)
RARE
Earnings Whisper ®
N/A
1st Quarter March 2026
Consensus: ($1.48)
Revenue: $168.72 Mil
Thursday
May 14
4:05 PM ET
Score
Grade
Tweet
Share
Watch
Sentiment
Analysts
Sentiment
Analysts
Tweet
Share
Watch
Latest EPS
Thursday, February 12, 2026
Ultragenyx Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Update
What do you expect when RARE reports earnings?
Beat
Meet
Miss
Where is RARE's stock price going from here?
Up
Flat
Down
Analysts
Score
Grade
Sentiment
Analysts
Pivots
Resistance
$22.37
$21.89
$21.57
$21.09
Support
$20.77
$20.29
$19.97
Tweet
Trends
Short-term Price
Intermediate-term Price
Long-term Price
Investors' Sentiment
Analysts' Sentiment
Earnings Estimates
Growth
Description
Ultragenyx Pharmaceutical Inc. is focused on the identification, acquisition, development and commercialization of novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases.
Peers
Vertex Pharmaceuticals
Bristol Myers Squibb
Eli Lilly
Merck & Co.
Pfizer
Regeneron Pharmaceuticals
Johnson & Johnson
BioMarin Pharmaceutical
ARRAY Technologies
Insmed
Expectations
›
Ultragenyx Pharmaceu
